Moxonidine Sandoz

Moxonidine, the active ingredient in Moxonidine Sandoz, is an imidazoline receptor agonist presented as a tablet for oral use. It treats essential hypertension in adult patients by lowering elevated blood pressure.

GNH USA supplies Moxonidine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine is used as an antihypertensive agent targeting the central imidazoline I1 receptors to control blood pressure.

Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary (essential) hypertension.

Moxonidine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Fatigue: feeling of reduced energy. - Dizziness: light‑headedness, especially on standing. - Headache: mild to moderate cranial pain. - Nausea: upset stomach with urge to vomit. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Liver enzyme elevation: abnormal hepatic function tests. - Skin rash: widespread or severe dermatologic reaction. - Depression or mood changes: notable alterations in mental state.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: regularly check to avoid excessive hypotension. - Renal impairment: adjust dose or use with caution in reduced kidney function. - Cardiovascular disease: use carefully in patients with existing heart conditions. - Discontinuation: avoid abrupt cessation; taper if clinically indicated. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Moxonidine can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Other centrally acting antihypertensives: may cause additive blood‑pressure lowering effects. - Potent CYP2D6 inhibitors: can increase plasma concentrations of moxonidine.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive response. - NSAIDs: can attenuate antihypertensive effect. - Beta‑blockers: may require dose adjustment. - ACE inhibitors or ARBs: monitor for excessive blood‑pressure reduction. - Alcohol: can increase dizziness and hypotension.